Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

A 2021 Look at the Increased Risk of Elmiron-associated Pigmentary Maculopathy

May 21, 2021 By Law Offices of Thomas J. Lamb, P.A.

We have reported previously on Elmiron-related eye damage, particularly that long-term use of the interstitial cystitis treatment drug Elmiron has been linked to maculopathy eye damage. In this post, we present a 2021 Elmiron medical journal article wherein it is estimated that around 20% of interstitial cystitis patients with long-term Elmiron use may eventually be diagnosed with Elmiron-associated pigmentary maculopathy.

In the March 2021 edition of Current Opinion in Ophthalmology, a medical journal article elaborated on the degree of increased risk of Elmiron-associated pigmentary maculopathy. Here is the Abstract for “Update on maculopathy secondary to pentosan polysulfate toxicity” which provides some important details:

Purpose of review: The aim of the present review is to provide a comprehensive summary of available knowledge regarding toxic maculopathy secondary to [Elmiron, or pentosan polysulfate sodium (PPS)].

Recent findings: [Elmiron (PPS) toxicity] was described in 2018, and additional studies characterize it as dysfunction of the retinal pigment epithelium centered on the posterior pole, which can progress despite drug cessation. Requisite exposure can be as little as 0.325 kg and 2.25 years but averages closer to 1–2 kg and 10–15 years. Multimodal imaging should include near-infrared reflectance, optical coherence tomography, and fundus autofluorescence. Cross-sectional studies demonstrate evidence correlating cumulative dosing and the likelihood/severity of maculopathy. Early estimates of prevalence range from 12.7 to 41.7% depending on dosing, with overall rates around 20%.

It is important to know that a patient does not need to have current Elmiron use right up until the time when their pigmentary maculopathy is diagnosed for it to be considered Elmiron-related eye damage.

We are currently investigating possible Elmiron lawsuits for patients with past Elmiron use diagnosed with pigmentary maculopathy. If we can assist you with an Elmiron-related eye damage legal case, you can submit an online Elmiron Case Evaluation Form or call us on our toll-free number: 800-426-9535.

[Read article in full at original source]

Elmiron

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Uncategorized

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.